Use of Neurotrophic Factor-alpha1/Carboxypeptidase E (CPE) to Treat Alzheimer Disease
Summary:
The NICHD is seeking licensees for development of Carboxypeptidase E (CPE) as a therapy for MCI or AD.
Monomeric and Oligomeric Compounds as Contraceptives and Endocrine Therapeutics
Summary:
NICHD is seeking research co-development partners and/or licensees for development of this invention as a male contraceptive.
Improved Gene Therapy Vectors for the Treatment of Glycogen Storage Disease Type Ia (GSD-1a)
Summary:
NICHD is seeking licensees for development of an adeno-associated viral (AAV) vectors for the treatment of glycogen storage disease type Ia (GSD-Ia).
Molecular Classification of Primary Mediastinal Large B Cell Lymphoma Using Formalin-Fixed, Paraffin-Embedded Tissue Specimens
Description of Technology:
Primary mediastinal B-cell lymphoma (PMBCL) is an aggressive type of non-Hodgkin lymphoma that mostly occurs in people between the ages of 30-40. It accounts for 5-7% of all aggressive lymphomas. The diagnosis of PMBCL is challenging as the histological features of PMBCL overlap with diffuse large B-cell lymphoma (DLBCL), another most common type of non-Hodgkin lymphoma. Available evidence suggests that PMBCL responds much more favorably to the DA-EPOCH-R chemotherapy regimen than to the standard R-CHOP regimen used to treat DLBCL.
A Viral Exposure Signature to Define and Detect Early Onset Hepatocellular Carcinoma
Summary:
NCI seeks proposals from parties interested in co-development and licensing opportunities to employ biomarker viral exposure signature in diagnostic assays of early onset HCC.
T-Cell Therapy Against Patient-Specific Cancer Mutations
Description of Technology:
Human cancers contain genetic mutations that are unique to each patient. Some of the mutated peptides are immunogenic, can be recognized by T cells, and therefore, may serve as therapeutic targets.
Peptide Hydrogels for Rate-Controlled Delivery of Therapeutics
Description of Technology:
Hydrogels represent an attractive controlled drug-delivery system that have been used in various clinical applications, such as: tissue engineering for wound healing, surgical procedures, pain management, cardiology, and oncology. High-water content of hydrogels confers tissue-like physical properties and the crosslinked fibrillar network enables encapsulation of labile small molecule drugs, peptides, proteins, nucleic acids, proteins, nanoparticles, or cells.
EGFRvIII Antibodies for the Treatment of Human Cancer
Summary:
The NCI seeks research co-development partners or licensees for monoclonal antibodies that specifically target cancer-expressed EGFR.
Description of Technology:
Epidermal growth factor receptor variant III (EGFRvIII) is a variant of EGFR that is an excellent target for immunotherapy because of its expression in cancer cells and not in normal cells.
Induced Pluripotent Stem Cells Derived from Patients with CEP290-associated Ciliopathies and Unaffected Family Members
Summary:
The National Eye Institute (NEI) seeks research collaborations and/or licensees for the use of iPS cells.
Inducible Activation Nucleic Acid Hybrid Switch for Conditional Generation of Oligonucleotides
Summary:
The NCI is looking for innovative companies interested in co-developing and/or licensing a novel nucleic-based therapy based on the conditional activation strategy.